Tonix Pharmaceuticals Holding Corp. (TNXP) — SEC Financial Statements & Analysis

Tonix Pharmaceuticals Holding Corp. (TNXP) is a pharmaceutical preparations company, incorporated in NV. Tonix Pharmaceuticals Holding Corp. trades on Nasdaq as: TNXP. Tonix Pharmaceuticals Holding Corp. (TNXP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Tonix Pharmaceuticals Holding Corp. carries a market cap of $212.27M, a P/E ratio of -1.33x, a P/B ratio of 0.95x, a P/S ratio of 7.29x, an enterprise value of $35.65M, and an EV/EBITDA multiple of -0.22x. On profitability, it posts a gross margin of 83.83%, an operating margin of -568.43%, a net margin of -548.64%, a Return on Equity (ROE) of -81.82%, a Return on Assets (ROA) of -72.34%, and a Return on Invested Capital (ROIC) of -375.09%. Per share, it reports EPS of $-9.60, diluted EPS of $-9.60, free cash flow per share of $-9.50, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 196.02% year-over-year, net income growth of 96.10% year-over-year, and EPS growth of -13.63% year-over-year. On the balance sheet, it maintains a current ratio of 6.61x, a quick ratio of 6.26x, working capital of $172.65M, a debt-to-equity ratio of 0.14x, a debt ratio of 0.13, an interest coverage ratio of -108.76x, free cash flow of $-158.11M (TTM), and net debt of $-176.62M. Figures sourced from SEC EDGAR.

Market Cap

$212.27M

P/E TTM

-1.33x

EPS TTM

$-9.60

P/B TTM

0.95x

ROE TTM

-81.82%

ROA TTM

-72.34%

Debt To Equity

0.14x

Free Cash Flow TTM

$-158.11M

Net Revenue TTM Growth 1Y

196.02%

Data as of 2026-06-30 · Source: SEC EDGAR